Emerging oligonucleotide therapeutics for rare neuromuscular diseases
Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition. For the majority of these diseases, there i...
Main Authors: | Aoki, Y, Wood, MJA |
---|---|
Format: | Journal article |
Language: | English |
Published: |
IOS Press
2021
|
Similar Items
-
Oligonucleotide-based therapies for neuromuscular disease
by: Douglas, A, et al.
Published: (2015) -
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
by: Tsoumpra, MK, et al.
Published: (2019) -
Advances in oligonucleotide drug delivery
by: Roberts, TC, et al.
Published: (2020) -
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
by: Ashok Verma
Published: (2018-01-01) -
Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
by: Gait, M, et al.
Published: (2018)